IL-13 Inhibition in Moderate to Severe Atopic Dermatitis: A Clinical Skills Curriculum to Support Evidence-Based Treatment Decisions

Effective management is crucial for improving the care of patients with moderate to severe atopic dermatitis (AD). In this program, HCPs will learn about the pathophysiologic contributions of IL-13 in AD and how to assess patient candidacy for therapies targeting IL-13 through interactive case challenges, expert commentaries, podcasts, and downloadable slides.

Share

Program Content

Activities

Atopic Dermatitis Treatment
Targeting IL-13: A New Era in Atopic Dermatitis Treatment 
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: December 12, 2025

Faculty

cover img faculity

Daniel C. Butler, MD

Assistant Dean Student Affairs
Associate Professor
Director, Inflammatory and Aging Skin Research Program
Division of Dermatology
University of Arizona College of Medicine, Tucson
Tucson, Arizona

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC and the National Eczema Association.

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Partners

National Eczema Association

ProCE Banner